THERAVANCE BIOPHARMA INC

Ticker: TBPH CUSIP: G8807B106 Class: Common Stock

Connor, Clark & Lunn Investment Management Ltd.'s Holding History (CIK: 0001596800)

Note: Option positions (PUT/CALL) are excluded.

Q4 2025

Shares 221,662 Value ($000) $4,147 Avg Close $16.59 Range $13.50 - $20.33

Q3 2025

Shares 174,837 Value ($000) $2,553 Avg Close $12.64 Range $10.82 - $14.87

Q2 2025

Shares 56,613 Value ($000) $624 Avg Close $9.72 Range $7.90 - $11.82

Q2 2024

Shares 16,023 Value ($000) $136 Avg Close $9.03 Range $8.13 - $10.44

Q1 2022

Shares 40,477 Value ($000) $387 Avg Close $9.80 Range $7.71 - $13.17

Q4 2021

Shares 33,034 Value ($000) $365 Avg Close $8.72 Range $7.30 - $11.24

Q3 2021

Shares 44,237 Value ($000) $327 Avg Close $11.19 Range $6.10 - $15.01

Period	Shares	Value ($000)	Average Close	Price Range
Q4 2025	221,662	$4,147	$16.59	$13.50 - $20.33
Q3 2025	174,837	$2,553	$12.64	$10.82 - $14.87
Q2 2025	56,613	$624	$9.72	$7.90 - $11.82
Q2 2024	16,023	$136	$9.03	$8.13 - $10.44
Q1 2022	40,477	$387	$9.80	$7.71 - $13.17
Q4 2021	33,034	$365	$8.72	$7.30 - $11.24
Q3 2021	44,237	$327	$11.19	$6.10 - $15.01